Molecular Markers of Prognosis and Novel Therapeutic Strategies for Urothelial Cell Carcinomas

Overview

Journal World J Urol

Specialty Urology

Date 2006 Oct 26

PMID 17063322

Citations 5

Authors

Christopher Y Thomas

Dan Theodorescu

Affiliations

Soon will be listed here.

Citing Articles

RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation.

Yang J, Platt L, Maity B, Ahlers K, Luo Z, Lin Z Oncotarget. 2016; 7(43):69159-69172.

PMID: 27713144 PMC: 5342467. DOI: 10.18632/oncotarget.12473.

New and promising strategies in the management of bladder cancer.

Apolo A, Vogelzang N, Theodorescu D Am Soc Clin Oncol Educ Book. 2015; :105-12.

PMID: 25993148 PMC: 6777550. DOI: 10.14694/EdBook_AM.2015.35.105.

Alterations of dendritic cell subsets and TH1/TH2 cytokines in the peripheral circulation of patients with superficial transitional cell carcinoma of the bladder.

Lang F, Linlin M, Ye T, Yuhai Z J Clin Lab Anal. 2012; 26(5):365-71.

PMID: 23001982 PMC: 6807352. DOI: 10.1002/jcla.21532.

Molecular markers in transitional cell carcinoma of the bladder: New insights into mechanisms and prognosis.

Ehdaie B, Theodorescu D Indian J Urol. 2009; 24(1):61-7.

PMID: 19468362 PMC: 2684226. DOI: 10.4103/0970-1591.38606.

Immunoscreening of urinary bladder cancer cDNA library and identification of potential tumor antigen.

Chen L, Chen W, Zhao L, Yu H, Li X World J Urol. 2008; 27(1):107-12.

PMID: 18828023 DOI: 10.1007/s00345-008-0326-4.

References

Pan J, Yeung S . Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res. 2005; 65(20):9109-12. DOI: 10.1158/0008-5472.CAN-05-2635. View

Galanis E, Buckner J, Maurer M, Kreisberg J, Ballman K, Boni J . Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005; 23(23):5294-304. DOI: 10.1200/JCO.2005.23.622. View

Kelly W, Richon V, OConnor O, Curley T, MacGregor-Curtelli B, Tong W . Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res. 2003; 9(10 Pt 1):3578-88. View

Billerey C, Chopin D, Aubriot-Lorton M, Ricol D, Gil Diez de Medina S, van Rhijn B . Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001; 158(6):1955-9. PMC: 1891972. DOI: 10.1016/S0002-9440(10)64665-2. View

Habuchi T, Marberger M, Droller M, Hemstreet 3rd G, Grossman H, Schalken J . Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology. 2006; 66(6 Suppl 1):64-74. DOI: 10.1016/j.urology.2005.08.065. View

Lipponen P, Eskelinen M . Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer. 1994; 69(6):1120-5. PMC: 1969432. DOI: 10.1038/bjc.1994.220. View

Messing E . Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res. 1990; 50(8):2530-7. View

Hitchings A, Kumar M, Jordan S, Nargund V, Martin J, Berney D . Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb. Br J Cancer. 2004; 91(3):552-7. PMC: 2409830. DOI: 10.1038/sj.bjc.6601954. View

OKane H, Watson C, Johnston S, Petak I, Watson R, Williamson K . Targeting death receptors in bladder, prostate and renal cancer. J Urol. 2006; 175(2):432-8. DOI: 10.1016/S0022-5347(05)00160-6. View

10.

Wilhelm S, Carter C, Tang L, Wilkie D, McNabola A, Rong H . BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64(19):7099-109. DOI: 10.1158/0008-5472.CAN-04-1443. View

11.

Jebar A, Hurst C, Tomlinson D, Johnston C, Taylor C, Knowles M . FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 2005; 24(33):5218-25. DOI: 10.1038/sj.onc.1208705. View

12.

Miller K, Chap L, Holmes F, Cobleigh M, Marcom P, Fehrenbacher L . Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005; 23(4):792-9. DOI: 10.1200/JCO.2005.05.098. View

13.

Mhawech-Fauceglia P, Cheney R, Fischer G, Beck A, Herrmann F . FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol. 2006; 32(2):231-7. DOI: 10.1016/j.ejso.2005.11.018. View

14.

Sarkis A, Dalbagni G, Cordon-Cardo C, Zhang Z, Sheinfeld J, Fair W . Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst. 1993; 85(1):53-9. DOI: 10.1093/jnci/85.1.53. View

15.

Mellon K, Wright C, Kelly P, Horne C, Neal D . Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol. 1995; 153(3 Pt 2):919-25. View

16.

Mhawech-Fauceglia P, Fischer G, Beck A, Cheney R, Herrmann F . Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up. Eur J Surg Oncol. 2006; 32(4):439-44. DOI: 10.1016/j.ejso.2006.01.018. View

17.

Lipponen P . Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer. 1993; 53(3):365-70. DOI: 10.1002/ijc.2910530304. View

18.

Kamai T, Takagi K, Asami H, Ito Y, Oshima H, Yoshida K . Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer. 2001; 84(9):1242-51. PMC: 2363875. DOI: 10.1054/bjoc.2000.1736. View

19.

Granville C, Memmott R, Gills J, Dennis P . Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res. 2006; 12(3 Pt 1):679-89. DOI: 10.1158/1078-0432.CCR-05-1654. View

20.

Deininger M, Druker B . Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev. 2003; 55(3):401-23. DOI: 10.1124/pr.55.3.4. View